I am a molecular parasitologist exploring parasitism in blood-feeding human helminths, with a particular focus on the molecular biology of parasite feeding and immune evasion. I am utilizing this information to develop anti-helminth recombinant vaccines a
Determining Immune Dynamics During Controlled Primary Infection In Humans
Funder
National Health and Medical Research Council
Funding Amount
$579,823.00
Summary
T cells are critical to human health being our second and last line against infectious disease and cancer. However, we know very little about how this hugely complex immune compartment operates during primary challenge with infectious disease. This project will use new technologies to resolve this immune compartment to high detail during the days, weeks and years following controlled infection in human volunteers.
Helminth Secretomes: From Vaccines To Novel Anti-inflammatory Biologics
Funder
National Health and Medical Research Council
Funding Amount
$938,910.00
Summary
Billions of people in developing countries are infected with parasitic worms, but they have been eradicated from industrialised nations. Humans co-evolved with worms, so their recent removal has deprived us of signals required to keep inflammation in check. My research focuses on worm molecules that can be used to (1) develop vaccines to combat these parasitic infections in developing countries, and (2) as a novel platform of anti-inflammatory therapeutics for use in industrialised nations.
A Cluster RCT Of The Impact Of A Community-based Hygiene And Sanitation Programme On Infection With Intestinal Parasites Following Mass Albendazole Chemotherapy In Timor-Leste
Funder
National Health and Medical Research Council
Funding Amount
$1,178,136.00
Summary
Intestinal parasites cause anaemia, stunting, wasting and poor mental development in childhood, and are related to poverty and poor hygiene. Treatment with antiparasitic drugs cures infections in human hosts, but does not prevent rapid re-infection when people contact a parasite-contaminated environment. We will quantify the impact of a hygiene and sanitation programme that reduces environmental contamination in communities that receive mass treatment with the antiparasitic drug albendazole.
Haemoglobin Degrading Proteases As Targets Of Anti-hookworm Vaccines
Funder
National Health and Medical Research Council
Funding Amount
$522,773.00
Summary
Blood-feeding worms ingest red blood cells and disrupt them in the intestine, releasing haemogobin (Hb). We have recently shown that canine hookworms employ a battery of distinct proteolytic enzymes, termed haemoglobinases, which digest Hb. The families of proteases used and the order in which they act are strikingly similar to the defined catalytic pathway used by the malaria parasite to digest Hb in its food vacuole. Recent work from our laboratory has shown that these proteases are effective ....Blood-feeding worms ingest red blood cells and disrupt them in the intestine, releasing haemogobin (Hb). We have recently shown that canine hookworms employ a battery of distinct proteolytic enzymes, termed haemoglobinases, which digest Hb. The families of proteases used and the order in which they act are strikingly similar to the defined catalytic pathway used by the malaria parasite to digest Hb in its food vacuole. Recent work from our laboratory has shown that these proteases are effective as vaccines against canine hookworm disease by interfering with the worm's ability to feed on blood and obtain suitable nutrition. This in turn affects the ability of female worms to lay eggs, thereby potentially disrupting transmission of the parasites. We now propose to identify the genes encoding haemoglobinases from the human hookworm, Necator americanus, determine the ordered pathway of Hb degradation and explore in vitro correlates of the effectiveness of a haemoglobinase vaccine in animal models of hookworm infection and pathogenesis.Read moreRead less
Next Generation Of Medical Devices And Diagnostics
Funder
National Health and Medical Research Council
Funding Amount
$2,738,220.00
Summary
This Investigator Project will deliver innovative technologies that improve patient wellbeing, make significant economic impact and contribute to answering complex biological questions. This will happen via delivering breakthrough technologies to prevent infections and diagnose diseases – two area that currently require substantial technological advances. In addition to helping patients and clinicians, the project will also deliver solid body of new knowledge that is currently missing.
Clinical Impact Of Clonal Pseudomonas Aeruginosa In Cystic Fibrosis
Funder
National Health and Medical Research Council
Funding Amount
$547,238.00
Summary
In patients with cystic fibrosis (CF), the normal defence mechanisms are compromised by an inherent genetic fault which results in an extremely sticky and dehydrated mucus. The respiratory system is unable to eradicate microbes (infection) from the lungs of patients with CF which begin to multiply and cause infection and inflammation. Recurring infections are treated with multiple courses of antibiotics and frequent hospitalisation and eventually result in premature death. This study focuses on ....In patients with cystic fibrosis (CF), the normal defence mechanisms are compromised by an inherent genetic fault which results in an extremely sticky and dehydrated mucus. The respiratory system is unable to eradicate microbes (infection) from the lungs of patients with CF which begin to multiply and cause infection and inflammation. Recurring infections are treated with multiple courses of antibiotics and frequent hospitalisation and eventually result in premature death. This study focuses on the major bacterial problem, Pseudomonas aeruginosa. Several studies from Australia and the UK, including our own have shown that about 30% to 45% of patients share the same strain of Pseudomonas aeruginosa within a centre. We know that two dominant strains of Pseudomonas aeruginosa are found in CF centres on the eastern board of Australia. This is unexpected as this bacterium is usually acquired from the environment. The emergence of these clonal strains is causing increasing anxiety in the CF community. This study is designed to provide vitally needed information on the clinical implications of being infected by an clonal strain of Pseudomonas aeruginosa and the risk factors for the acquisition of an clonal strain. This new information will provide a rationale basis for the need for changes to infection control policies (including patient segregation), better outcome predictors for patients infected with clonal strain of Pseudomonas aeruginosa.Read moreRead less
Treatment Of Cerebral Palsy - An Experimental Approach
Funder
National Health and Medical Research Council
Funding Amount
$589,544.00
Summary
Cerebral palsy is characterised by disordered movement evident early in life leading to lifelong disability. The motor disorder arises from an abnormality within the white-matter of the brain that is non-progressive and is identifiable soon after birth. In humans and experimental models of fetal infection there is an increase in markers of inflammation. We will use induce ovine fetal infection and white matter injury to examine if anti-inflammatory treatments can prevent fetal brain damage.